Is loplastin/romilastin the most recommended?

Romiplostim is used to treat immune thrombocytopenia (ITP), an autoimmune disease in which a patient's immune system produces autoantibodies that mistakenly attack and destroy platelets, causing low levels of platelets in the blood. Platelets are blood cells produced by the bone marrow and circulate in the blood. Normally, these cells clump together (stick together) during an injury or cut to seal damaged blood vessels and limit excess blood loss.

InITP, however, the patient's body experiences difficulty stopping bleeding due to low platelet count, ultimately increasing the risk of severe internal or external bleeding or bruising. Roplastin is used to maintain platelet counts at least 50,00/L or above to prevent bleeding events or bruising associated with ITP. The U.S. Food and Drug Administration (FDA) approved the drug only to treat thrombocytopenia caused by ITP, not thrombocytopenia caused by other medical diseases such as myelodysplastic syndrome (MDS). In some cases, ropremilast is also used to improve survival in patients whose bone marrow has been affected by exposure to myelosuppressive (bone marrow-suppressing) doses of radiation.

The decision to purchase and use Roprostim should be based on many considerations, including the patient's condition, treatment needs, potential side effects, and economic factors. For those patients with extremely low platelet counts who are at risk for bleeding, loprostim can effectively increase platelet levels, thereby reducing the incidence of bleeding. Roprostim is usually more expensive and requires long-term use to maintain efficacy. For some patients, patients should consider their financial situation and explore insurance coverage and possible ancillary payment options before deciding whether to purchase.